Beijing Tiantan Biological Products Corp Ltd (600161) Income Statement

An income statement shows a company's revenue, expenses, and profit over a reporting period.

Beijing Tiantan Biological Products Co., Ltd. engages in the research and development, manufacture, sale, and marketing of blood products in China and internationally.

Total Revenue Chart for Beijing Tiantan Biological Products Corp Ltd

Beijing Tiantan Biological Products Corp Ltd (600161) revenue for FY2025 was CNY 6.1B, a 1.8% change from FY2024. Beijing Tiantan Biological Products Corp Ltd's revenue grew from CNY 100.3M in 1995 to CNY 6.1B in 2025 (6021.6% over 30 years). Earnings per share grew from CNY 0.03 in 2000 to CNY 0.53 in 2022 (1584.1%). Revenue compound annual growth rate: 5-year CAGR of 12.2%, 10-year CAGR of 14.3%, 20-year CAGR of 15.5%.

The most recent 8 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Revenue (CNY)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
¥24.28B
Implied Share Price
¥12.28
Enterprise Value
¥22.09B
Revenue (TTM)
¥5.65B
EBITDA
¥1.68B
Profit Margin
13.39%
Trailing P/E
32.32
Forward P/E
17.67
Price/Book (MRQ)
2.02
Price/Sales (TTM)
4.30
EV/EBITDA
12.60
EV/Revenue
3.91
Dividend Yield
1.64%
Book Value
¥6.33
Free Cash Flow (FY2025)
-¥229.59M
Free Cash Flow Yield
-0.95%

Snapshot as of 5th September 2026 — not point-in-time controlled, may lag the live market by a few days.